These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 21934531)

  • 1. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
    Fu H; Hosomi N; Pelisch N; Nakano D; Liu G; Ueno M; Miki T; Masugata H; Sueda Y; Itano T; Matsumoto M; Nishiyama A; Kohno M
    J Hypertens; 2011 Nov; 29(11):2210-9. PubMed ID: 21934531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postischemic administration of angiotensin II type 1 receptor blocker reduces cerebral infarction size in hypertensive rats.
    Omura-Matsuoka E; Yagita Y; Sasaki T; Terasaki Y; Oyama N; Sugiyama Y; Okazaki S; Sakoda S; Kitagawa K
    Hypertens Res; 2009 Jul; 32(7):548-53. PubMed ID: 19424281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between early and delayed systemic treatment with candesartan of rats after ischaemic stroke.
    Brdon J; Kaiser S; Hagemann F; Zhao Y; Culman J; Gohlke P
    J Hypertens; 2007 Jan; 25(1):187-96. PubMed ID: 17143191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.
    Krikov M; Thone-Reineke C; Müller S; Villringer A; Unger T
    J Hypertens; 2008 Mar; 26(3):544-52. PubMed ID: 18300867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia.
    Hosomi N; Nishiyama A; Ban CR; Naya T; Takahashi T; Kohno M; Koziol JA
    Neuroscience; 2005; 134(1):225-31. PubMed ID: 15963646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candesartan attenuates ischemic brain edema and protects the blood-brain barrier integrity from ischemia/reperfusion injury in rats.
    Panahpour H; Nekooeian AA; Dehghani GA
    Iran Biomed J; 2014; 18(4):232-8. PubMed ID: 25326022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of angiotensin II type 1 receptor blocker, candesartan, and beta 1 adrenoceptor blocker, atenolol, on brain damage in ischemic stroke.
    Saad MA; Abbas AM; Boshra V; Elkhateeb M; El Aal IA
    Acta Physiol Hung; 2010 Jun; 97(2):159-71. PubMed ID: 20511125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R; Högemann AM; Sunzel M; Riddell JG
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection.
    Elewa HF; Kozak A; Johnson MH; Ergul A; Fagan SC
    J Hypertens; 2007 Apr; 25(4):855-9. PubMed ID: 17351379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
    Elmfeldt D; George M; Hübner R; Olofsson B
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S49-53. PubMed ID: 9331007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.
    Fagan SC; Kozak A; Hill WD; Pollock DM; Xu L; Johnson MH; Ergul A; Hess DC
    J Hypertens; 2006 Mar; 24(3):535-9. PubMed ID: 16467657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and 3-month treatment effects of candesartan cilexetil on hemodynamics, neurohormones, and clinical symptoms in patients with congestive heart failure.
    Mitrovic V; Willenbrock R; Miric M; Seferovic P; Spinar J; Dabrowski M; Kiowski W; Marks DS; Alegria E; Dukát A; Lenz K; Arens HA
    Am Heart J; 2003 Mar; 145(3):E14. PubMed ID: 12660683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.
    Lange SA; Wolf B; Schober K; Wunderlich C; Marquetant R; Weinbrenner C; Strasser RH
    J Cardiovasc Pharmacol; 2007 Jan; 49(1):46-55. PubMed ID: 17261963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
    Engelhorn T; Doerfler A; Heusch G; Schulz R
    Neurosci Lett; 2006 Oct; 406(1-2):92-6. PubMed ID: 16901636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of neuroprotective effect of single and combined blockade of AT1 receptor and PARP-1 in focal cerebral ischaemia in rat.
    Singh N; Sharma G; Singh N; Hanif K
    Int J Stroke; 2014 Jul; 9(5):560-8. PubMed ID: 23013350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats.
    Engelhorn T; Goerike S; Doerfler A; Okorn C; Forsting M; Heusch G; Schulz R
    J Cereb Blood Flow Metab; 2004 Apr; 24(4):467-74. PubMed ID: 15087716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of inhibitory action of candesartan and enalapril on brain ischemia through inhibition of oxidative stress.
    Hamai M; Iwai M; Ide A; Tomochika H; Tomono Y; Mogi M; Horiuchi M
    Neuropharmacology; 2006 Sep; 51(4):822-8. PubMed ID: 16824557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Developmental activity of the renin-angiotensin system during the "critical period" modulates later L-NAME-induced hypertension and renal injury.
    Ishiguro K; Sasamura H; Sakamaki Y; Itoh H; Saruta T
    Hypertens Res; 2007 Jan; 30(1):63-75. PubMed ID: 17460373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
    Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.